News

Epitomics Signs Collaboration Agreement with Simcere to Develop Therapeutic Monoclonal Antibodies

SAN FRANCISCO, CA - January 21, 2009

Epitomics, Inc., the world’s sole provider of humanized rabbit monoclonal antibodies for therapeutic use announced today an agreement to collaborate with Simcere Pharmaceutical Group (NYSE: SCR) on the co-development and production of humanized RabMAb® antibody therapeutics for multiple tumors. Simcere is a leading manufacturer and supplier of branded pharmaceuticals, and manufacturer of the patented anti-cancer biotech product Endu (also known as Endostar) in China.

With several recently issued industry-changing patents, Epitomics has established its proprietary RabMAb as a unique antibody technology and this collaboration agreement confirms Epitomics’ entry into the human therapeutics market. Under the agreement, Epitomics and Simcere will work in partnership on pre-clinical and clinical trials, product manufacturing, and product distribution in the international markets. Simcere will have the exclusive production and distribution rights in China.

“This is a unique product development opportunity for both companies, combining Epitomics’ superior RabMAb technology with the established success of Simcere’s oncology therapeutics,” said Dr. Guo-Liang Yu, CEO of Epitomics. “Monoclonal antibodies for therapeutic use have tremendous market potential in oncology and this partnership maximizes both companies’ research capabilities and firm commitment to quality.”

About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in the rapidly growing China market. In recent years, Simcere has been focusing its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic stroke management medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. Simcere currently manufactures and sells more than 50 pharmaceutical products including antibiotics, anti-cancer medication and stroke management medication. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases and currently has more than 12 pipeline products. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com

About Epitomics
Epitomics, Inc., an emerging biotechnology company, is dedicated to developing breakthrough monoclonal antibody technology for research, diagnostic and therapeutic applications. The Company utilizes a unique and proprietary RabMAb® (Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity and bioactivity in a wide variety of biological assays. Epitomics, Inc. is headquartered in Burlingame, California, and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China.